Article ; Online: Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Combination Therapy in Patients With Coronavirus Disease 2019 and Primary Antibody Deficiency.
The Journal of infectious diseases
2021 Volume 225, Issue 5, Page(s) 820–824
Abstract: Background: Previous reports highlighted the efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific monoclonal antibodies (mAbs) against coronavirus disease 2019.: Methods: We conducted a prospective study on the clinical ... ...
Abstract | Background: Previous reports highlighted the efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific monoclonal antibodies (mAbs) against coronavirus disease 2019. Methods: We conducted a prospective study on the clinical outcome and antiviral effects of mAbs added to standard of care therapy in SARS-CoV-2-infected patients with primary antibody defects. Results: Median time of SARS-CoV-2 quantitative polymerase chain reaction (qPCR) positivity was shorter in 8 patients treated with mAbs (22 days) than in 10 patients treated with standard of care therapy only (37 days, P=.026). Median time of SARS-CoV-2 qPCR positivity from mAb administration was 10 days. Conclusions: The SARS-CoV-2 mAbs treatment was effective and well tolerated in patients with primary antibody defects. |
---|---|
MeSH term(s) | Antibodies, Monoclonal/immunology ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Viral/immunology ; Antibodies, Viral/therapeutic use ; Antineoplastic Agents, Immunological ; COVID-19/drug therapy ; Common Variable Immunodeficiency ; Humans ; Primary Immunodeficiency Diseases/drug therapy ; Prospective Studies ; Real-Time Polymerase Chain Reaction ; SARS-CoV-2/isolation & purification ; Standard of Care |
Chemical Substances | Antibodies, Monoclonal ; Antibodies, Viral ; Antineoplastic Agents, Immunological |
Language | English |
Publishing date | 2021-10-26 |
Publishing country | United States |
Document type | Journal Article ; Research Support, Non-U.S. Gov't |
ZDB-ID | 3019-3 |
ISSN | 1537-6613 ; 0022-1899 |
ISSN (online) | 1537-6613 |
ISSN | 0022-1899 |
DOI | 10.1093/infdis/jiab554 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Uh II Zs.50: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
|||
Zs.MO 445: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.